

PRESS RELEASE

1 August 2011

**Babraham Bioscience Technologies Ltd.
Cambridge, UK**

Babraham Bioscience Technologies (BBT) becomes a One Nucleus Partner

BBT and One Nucleus have formed a strategic Partnership, which includes a strong package of support to offer a range of One Nucleus member benefits to both new and existing companies on the Babraham Research Campus.

Both BBT and One Nucleus are committed to playing an active and supportive role in assisting in the success of life sciences companies in the region and beyond and look forward to developing this relationship to provide valuable benefits to the life science community.

Derek Jones, Chief Executive of BBT commented, "One Nucleus is our natural partner of choice to collaborate with to offer tangible financial and commercial benefits to our tenant companies. We have a long-standing relationship built on trust and mutual goals and I look forward to our tenants profiting from One Nucleus membership long into the future."

Harriet Fear, CEO of One Nucleus said, "Our Partner Programme is a new initiative and we are delighted that BBT is the first science park locally to become a Partner. The Partner Programme is our new bespoke service, whereby we tailor a package of support to the needs of the organisation with a view to supporting them achieve their specific objectives."

Contact details:

Dr Claire Cockcroft
Head, External Relations
The Babraham Institute
Email: claire.cockcroft@bbsrc.ac.uk
Tel: +44 (0)1223 496260
Mobile: +44 (0)7786 335978

Mrs Nicola Kinsey,
Senior Operations Manager
Babraham Bioscience Technologies Limited
Email: nicola.kinsey@babraham.co.uk
Tel: +44 (0)1223 496334

The Babraham Research Campus
Cambridge CB22 3AT
United Kingdom

One Nucleus

Harriet Fear
Tel: +44 (0) 1223 896 454
harriet@onenucleus.com

Notes to Editors:

Babraham Bioscience Technologies Ltd, the commercial arm of the Babraham Institute, promotes, supports and encourages academic and commercial biomedical research locally, regionally and nationally. BBT delivers the Knowledge Exchange and Commercialisation (KEC) remit of the Institute – which receives strategic support from the Biotechnology and Biological Sciences Research Council (BBSRC) – and is responsible for managing the Babraham Research Campus' Bioincubator, currently home to around 30 early-stage biomedical companies. BBT brings together all the elements to support innovation and enable the successful exploitation of research in the biomedical sector based on technologies emanating from the Babraham Institute and bioventures relocating to the campus. BBT has taken a prominent role regionally, initiating and leading partnerships to promote knowledge

and skills flow and has established a reputation for successfully translating innovative science into viable business opportunities through partnerships for wealth creation. Website: www.babraham.com

The Babraham Institute, which receives strategic support from the Biotechnology and Biological Sciences Research Council (BBSRC), undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The Institute's research aims to understand the biological events that underlie the normal functions of cells and the implication of abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. (www.babraham.ac.uk)

One Nucleus: Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 450 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers